Company Filing History:
Years Active: 2021-2023
Title: Innovations by Inventor Markus Zettl
Introduction
Markus Zettl is a prominent inventor based in Vienna, Austria. He has made significant contributions to the field of cancer treatment through his innovative research and development of antibody molecules. With a total of 3 patents, Zettl is recognized for his work in advancing therapeutic options for cancer patients.
Latest Patents
Zettl's latest patents include groundbreaking inventions aimed at improving cancer treatment. One of his notable patents is for antibody molecules that target PD1 and LAG3. This invention encompasses novel anti-PD1 and anti-LAG3 antibody molecules, along with nucleic acids encoding these antibodies. It also details methods for preparing these antibody molecules, host cells capable of expressing them, and their therapeutic uses in cancer diseases. Another significant patent involves antagonizing CD73 antibodies, which also includes nucleic acids, preparation methods, and therapeutic applications in the field of cancer.
Career Highlights
Markus Zettl is currently associated with Boehringer Ingelheim International GmbH, where he continues to push the boundaries of cancer research. His work has been instrumental in developing new therapeutic strategies that could potentially improve patient outcomes.
Collaborations
Zettl collaborates with esteemed colleagues such as Otmar Schaaf and Melanie Wurm, contributing to a dynamic research environment focused on innovative cancer therapies.
Conclusion
Markus Zettl's contributions to cancer treatment through his patented inventions highlight his role as a leading inventor in the field. His work not only advances scientific knowledge but also holds the promise of improving the lives of many patients battling cancer.